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Stroke is a leading cause of disability, dementia and 
mortality worldwide and is associated with substantial 
economic costs. Globally, an average of 1 in 4 adults 
will have a stroke during their lifetime1. Global, 
age- standardized stroke mortality rates declined sub-
stantially between 1990 and 2016, most likely as a result 
of the increased availability of acute stroke treatments 
and improved inpatient care in high- income coun-
tries; however, the decline in incidence was less steep 
in Africa2. The 2019 update on global stroke statistics 
identified a consistent increase in stroke incidence in 
low- income and middle- income countries (LMICs) on 
the basis of stroke incidence studies performed between 
1971 and 2014 (ref.3). Between 1970 and 2010, 70% of 
all stroke deaths and 87% of disability owing to stroke 
occurred in LMICs3,4.
The burden of non- communicable diseases is increas-
ing exponentially in Africa. In addition, infections such 
as malaria, human immunodeficiency virus (HIV) and 
tuberculosis persist and are further exacerbated by 
poverty and conflict5,6. We are also witnessing an increase 
in the co- morbidity of non- communicable and commu-
nicable diseases7,8. Less than a century ago, stroke was 
relatively uncommon in Africa9,10. However, in recent 
systematic analyses by the global burden of neurological 
diseases investigators, stroke was foremost along with 
migraine and meningitis in terms of disability- adjusted 
life years (DALYs) in northern, central, western, eastern 
and southern Africa11. Today, Africa has some of the 
highest indices of stroke burden in the world4,12–14. 
The increase in stroke burden in Africa is being driven 
by multiple factors acting across the lifespan. Key 
drivers include in utero and early- life undernutrition, 
which are associated with increased cardiometabolic risk 
factors in mid- life15–17, increasing exposure to indoor 
and outdoor particulate air pollution18,19, changes in 
dietary habits and population ageing20. These rela-
tionships are only the tip of the iceberg because, 
for every case of clinical stroke, there are four other 
cases of covert or ‘silent strokes’, which can cause 
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cognitive dysfunction and mental health conditions in later 
years19,21,22.
Stroke medicine in Africa has advanced over the 
past decade. Our understanding of both traditional 
and emerging risk factors, including their effect sizes and 
population attributable risk (PAR), has improved. More 
information on stroke aetiology and pathophysiological 
types and subtypes is now available for African popula-
tions, including a better understanding of strokes that 
occur as a consequence of sickle cell disease (SCD), 
HIV/AIDS or SARS- CoV-2 (COVID-19) infection. 
Stroke outcomes, rehabilitation, cost of care, quality of 
life and mortality are receiving more detailed attention, 
while post- stroke complications, including cognitive 
impairment and dementia, anxiety and depression, 
fatigue, and seizure disorders, are increasingly docu-
mented in the growing stroke literature from Africa4,12. 
Candidate- gene studies and ongoing genome- wide asso-
ciation studies (GWAS) have also begun to elucidate the 
genetic architecture of stroke in Africa23–25.
Despite this progress, substantial gaps remain in our 
understanding of stroke in Africa as well as in stroke 
care, practice and policy on the continent. The effective 
organization of preventative, therapeutic and rehabili-
tative stroke services also remains a challenge in many 
African countries. However, emerging insights from 
research and the introduction of novel stroke leadership 
initiatives offer huge prospects for tackling the growing 
burden of stroke on the continent with context- sensitive 
strategies. In this article, we review the unique epide-
miological, aetiological and genetic profiles of stroke in 
Africa and summarize what we know about stroke 
prevention, acute care, rehabilitation, cost of care, out-
comes and awareness. We also identify knowledge gaps, 
emerging priorities and future directions for stroke 
medicine and care and the implications for the people 
of Africa and the global community.
Stroke epidemiology in Africa
Several epidemiological studies have been undertaken on 
stroke in Africa with a preponderance of hospital- based 
over community or population survey studies. Several 
of the population- based studies have been identified as 
having methodological shortcomings26,27 and the only 
study that fulfilled the gold- standard criteria for a stroke 
epidemiological study was a prevalence study performed 
in urban Egypt (Al Quseir) by El- Tallawy et al.28.
Incidence
In 1991, a study involving hospital patients estimated 
the annual stroke incidence in Harare, Zimbabwe, to 
be 31 per 100,000 individuals29. Other hospital- based 
incidence studies from Benghazi, Libya (1984 (ref.30) 
and 1993 (ref.31)), urban Pretoria, South Africa32 
(1985) and Maputo, Mozambique (2006)33 reported 
annual crude incidence rates ranging from 48 to 
149 per 100,000 individuals. However, hospital- based 
studies do not adequately capture the true burden of 
stroke within a given community because the popula-
tion at risk is not known, thus interpretation of such 
studies requires caution. Indeed, a continent- wide 
meta- analysis34 and a Nigeria- based meta- analysis35 
of pooled estimates of stroke incidence both found 
that hospital- based studies estimated lower incidence 
rates than community- based studies, suggesting that 
hospital- derived data under- represent the true incidence 
of stroke.
The earliest known community- based study of 
stroke incidence in Africa was derived from the Ibadan 
Stroke Registry and was conducted from 1973 to 1975 
in Ibadan, an urban city in southwestern Nigeria. The 
study reported an annual crude incidence rate of 26 per 
100,000 individuals36. Similar studies from Lagos and 
Akure, southwestern Nigeria, were conducted in 2007 
and 2010 and reported annual crude incidence rates of 
25 per 100,000 (ref.37) and 61 per 100,000, respectively38. 
Other community- based studies have been undertaken 
Key points
•	the annual incidence rate of stroke in Africa is up to 316 per 100,000 individuals, 
which is within the highest incidence rates in the world, and the prevalence rate of 
1,460 per 100,000 reported in one region of Nigeria, western Africa, is clearly among 
the highest in the world.
•	Hypertension remains the most important modifiable risk factor for stroke in Africa 
but others include diabetes mellitus, dyslipidaemia, obesity, stress, smoking, alcohol 
use, physical inactivity and an unhealthy diet.
•	Africa has a slightly greater preponderance of small vessel disease- related stroke and 
intracerebral haemorrhagic lesions than elsewhere in the world.
•	the results of the first African genome- wide association study on stroke are expected 
soon but genes already known to modify stroke risk in African populations include IL6, 
APOE, APOL1, CYB11B2 and CDKN2A/2B.
•	Pragmatic approaches to improving stroke care in Africa include regular monitoring 
of risk factors and health services, implementation of prevention strategies, improving 
acute care and rehabilitation services, and encouraging task sharing; the emergence 
of standalone stroke care and stroke units in some North African and sub- Saharan 
countries is encouraging.
•	Numerous challenges face stroke medicine in Africa but awareness and the concerted 
efforts towards securing support for more stroke research and services via 
organizations such as the African Stroke Organization, World Stroke Organization 
and WHO hold much promise.
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in other parts of the continent28,39,40 (Table 1) and have 
reported crude annual stroke incidence rates ranging 
from 95 per 100,000 in rural Tanzania, East Africa13, 
to 260 per 100,000 in urban Egypt, North Africa40. 
The variation in the reported figures might result from 
methodological differences, such as completeness of 
case ascertainment, inclusion of mild or clinically cov-
ert strokes, lack of differentiation between first and 
Table 1 | Studies of stroke incidence and prevalence in Africa
Country, region Study 
period
















Incidence: annual range 25–260 per 100,000 from 1973 to 2013
Nigeria, Ibadan 1973–1975 Community Not stated No Yes 26 Not stated 36
Libya, Benghazi 1983–1984 Hospital US national 
survey of stroke
Yes Yes 63 Not stated 30
South Africa, Pretoria 1984–1985 Hospital Harvard 
Cooperative 
Stroke Registry
Yes Yes 101 Not stated 32
Zimbabwe, Harare 1991 Hospital WHO criteria No No 31 68 29
Libya, Benghazi 1991–1993 Hospital Not stated Yes Yes 48 Not stated 31
Egypt, Sohag 1992–1993 Community WHO criteria Yes Yes 180 Not stated 39
Tanzania, Hai 2003–2006 Mixed WHO criteria Yes Yes 95 109 13
Tanzania, Dar es Salaam 2003–2006 Mixed WHO criteria Yes Yes 108 316 13
Mozambique, Maputo 2005–2006 Hospital WHO criteria Yes Yes 149 260 33
Egypt, Al- Kharga 2005–2008 Community WHO criteria Yes No 260 560 40
Nigeria, Lagos 2007 Community WHO criteria Yes No 25 54 37
Egypt, Al- Quseir 2010–2011 Community WHO criteria Yes No 181 Not stated 28
Nigeria, Akure 2010– 2011 Mixed Not stated Yes Yes 61 61 38
Prevalence: crude range 15–1,331 per 100,000 from 1983 to 2016
Nigeria, Igbo- Ora, rural 1983–1984 Community WHO criteria No No 56 Not stated 42
Tunisia, Kelibia 1985 Community WHO criteria Yes Yes 42 Not stated 46
Ethiopia, central and rural 1988 Community WHO criteria No No 15 Not stated 44
Egypt, Sohag 1992–1993 Community WHO criteria Yes Yes 508 Not stated 39
Tanzania, Hai 1994–1995 Community WHO criteria No Yes 127 Not stated 43
South Africac, Limpopo 
province, rural
2001 Community WHO criteria No Yes 243 300 47
Nigeria, Lagos, urban 2007 Community WHO criteria No No 114 204 48
Egypt, Al- Kharga 2005–2009 Community WHO criteria Yes Yes 580 Not stated 40
Nigeria, Niger Delta 2008 Community WHO criteria No No 851 1,230 49
Benin, Cotonou, urban 2008–2009 Community WHO criteria Yes Yes 460 771 50
Morocco, Rabat 2008–2009 Community WHO criteria Yes Yes 284 292 51
Nigeria, Kwara, 
semi- urban
2009–2010 Community WHO criteria No No 1,310 Not stated 52
Tanzania, Hai 2009–2010 Community WHO criteria No No 2,420  




Egypt, Assiut 2010 Community WHO criteria Yes Yes 963 980 45
Egypt, Al Quseird 2010–2011 Community WHO criteria Yes Yes 655 Not stated 28
Nigeria, SE 2011 Community WHO criteria No No 163 163 54
Egypt, Qena 2011–2013 Community WHO criteria Yes Yes 922 567 55
Nigeria, Niger Delta 2014 Community WHO criteria No No 1,331 1,460 14
Nigeria, Odeda 2015 Community WHO criteria No No 711 Not stated 56
Benin, Parakou 2016 Community WHO criteria No Yes 1,156 3,223 57
a‘Yes’ >80%. bPer 100,000 population. cSouth Africa, Agincourt Health and Population Unit. dThe prevalence study performed in urban Egypt (Al Quseir) by  
El-​Tallawy​et al.​fulfilled​the​gold-​standard​criteria​for​a​stroke​epidemiological​study.
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recurrent strokes, and use of neuroimaging for diag-
nostic confirmation and subtyping. Other sources of 
variation include inherent geographical differences in 
the distribution of risk factors, differences in genetic 
susceptibility to stroke across the populations studied, 
and cohort or period effects23,26,41.
Age- adjusted incidence rates are more representative 
of the distribution of stroke among the population, espe-
cially in Africa, where the population is predominantly 
<60 years of age26. The most recent and rigorous study 
of stroke incidence in Africa was performed in Tanzania 
and published in 2010 (ref.13). The age- standardized 
stroke incidence rates from the two surveillance sites 
in Hai (rural Tanzania) and Dar es Salaam (urban 
Tanzania) were 109 and 316 per 100,000 person- years, 
respectively13. WHO world population data were used 
for age- standardization and the researchers used a robust 
case- ascertainment strategy. If the incidence rates from 
this study are extrapolated to the rest of Africa, it implies 
that every minute, six Africans have a stroke. The Dar es 
Salaam rates were similar to the highest rates in South 
East Asia and Europe, according to the Global Burden 
of Disease (GBD) study on global, regional and national 
burden of stroke, which reported the age- standardized 
stroke incidence rate as 354 per 100,000 person- years 
in China and 335 per 100,000 person- years in Latvia2.
Prevalence
The 1982 Igbo- Ora community prevalence study in rural 
southwestern Nigeria was one of the earliest of such stud-
ies to be performed in Africa and found a crude stroke 
prevalence of 58 per 100,000 (ref.42). The largest commu-
nity prevalence study on stroke in Africa was performed 
in 1994 in the rural Hai district of Tanzania and reported 
an age- standardized prevalence of 154 per 100,000 in 
men >15 years of age and 114 per 100,000 in women 
>15 years of age43. Other crude prevalence estimates of 
stroke from community studies in Africa range from 
15 per 100,000 in rural Ethiopia44 to 963 per 100,000 
in urban Egypt45, with more recent studies reporting 
higher stroke prevalence than older studies14,28,39,40,45–57 
(Table 1). Age- adjusted stroke prevalence seems to be 
higher in some parts of Africa than the global average. 
For example, two studies from rural communities in 
the Niger Delta region of southern Nigeria reported 
age- adjusted prevalence rates of 1,230 per 100,000 (ref.49) 
and 1,460 per 100,000 (ref.14). According to data from 
the GBD study, global age- adjusted stroke prevalence 
increased from 1,261 (95% uncertainty interval (UI) 
1,208.2–1,318.7) per 100,000 person- years in 1990 to 
1,300.6 (UI 1,229–1,374.7) per 100,000 person- years 
in 2017 (ref.58). Therefore, although stroke prevalence is 
declining in western Europe and North America, Africa 
might have some of the highest stroke prevalence rates 
in the world.
Frequencies in hospitals
In Africa, hospital- based studies on stroke seem to 
be more common than community- based or popu-
lation survey- based studies59–68. The results of these 
hospital- based studies indicate that stroke is the leading 
cause of adult neurological admissions and medical coma. 
In one hospital- based case series, stroke accounted for 
up to 78% of adult neurological admissions69. In another 
tertiary centre, stroke accounted for up to 57% of indi-
viduals admitted with medical coma61. The results of a 
hospital- based cross- sectional cohort study indicated 
that stroke constituted ~25% of medical admissions 
among patients aged ≥60 years in Nigeria, Sudan and 
Tanzania67. A male preponderance in stroke presenta-
tion in African hospitals was generally observed in 
these studies56–65. A comparative study found ischae-
mic stroke to be the predominant stroke phenotype in 
Africa, accounting for up to 73% of stroke admissions; 
however, the burden of haemorrhagic stroke was higher 
in Indigenous Africans than in African Americans or 
Americans of European descent70. Indeed, a separate 
study, performed in southwestern Nigeria, reported 
that haemorrhagic strokes constituted ~45% of all stroke 
admissions65.
Mortality and fatality rates
The results of population- based studies suggest that 
mortality after stroke is high in Africa — estimates of 
stroke- related deaths as a proportion of overall mor-
tality range from 5.5%62 to 11%63,71,72. The crude stroke 
mortality rate in a 1992–1995 study in Agincourt, South 
Africa, was estimated at 127 per 100,000 in individuals 
>35 years of age, although a 2016 study from the same 
site found a mortality rate of 114 per 100,000 (refs47,73). 
A Tanzanian study on stroke mortality at three sites 
(one urban, two rural) found yearly age- adjusted stroke 
mortality of up to 88 per 100,000 for men and 44 per 
100,000 for women71. However, the results of stroke mor-
tality studies in Africa require cautionary interpretation, 
owing to low levels of standardized death registration 
and the use of verbal autopsies.
Evidence suggests that the case fatality rate for stroke 
could be higher in parts of Africa than in the rest of the 
world. In hospital- based studies from Africa, incident 
case fatality at 30 days ranges from 16.2% to 46%73,74. 
A systematic review and meta- analysis of stroke case 
fatality in sub- Saharan Africa was published in 2021 and 
reported a pooled estimated 1- month case fatality rate of 
24.1%, with high heterogeneity and rates up to 83.3%75. 
These data contrast with the 1- month case fatality rates 
in high- income countries reported in a 2009 review by 
Feigin et al., ranging from 8% in France to 49.2% in 
Estonia76. In Africa, case fatality rates are generally higher 
for haemorrhagic strokes than ischaemic strokes74,77–82. 
Studies with a longer follow- up period, such as those 
performed by Walker et al. in Tanzania, have reported 
case fatality rates of up to 84.3% at 3 years post- stroke 
(rural Tanzania) and 82.3% at 7 years post- stroke (rural 
and urban Tanzania)72,83. Advanced age, stroke severity 
at presentation, in- hospital complications (especially 
aspiration pneumonia and sepsis) and poor functional 
status have been identified as predictors of post- stroke 
mortality72,83–86. Evidence indicates that early stroke fatal-
ity is further accentuated by poor control of metabolic 
risk factors (blood pressure, blood sugar), delayed stroke 
recognition and hospital presentation, and difficulties 
accessing early post- stroke care75,85–87. In addition, the 
nature and organization of stroke services in Africa 
NAture revIeWS | NEuROlOGY
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present inherent challenges, including limited access to 
diagnostic and time- dependent interventional services 
such as reperfusion therapies and stroke surgery, lack of 
stroke units and difficulty with patient retention during 
post- stroke rehabilitation88.
Disability- adjusted life years
Data regarding stroke DALYs in Africa are sparse. One 
systematic review found that the burden of disease 
owing to stroke in South Africa was 564,000 DALYs 
in 2008 (ref.89). In the few available studies, estimated 
DALYs lost due to stroke ranged from 1,070 DALYs per 
100,000 person- years in South Africa to 7,738 DALYs 
per 100,000 person- years in Kenya. Women seem to 
have more stroke- associated DALYs than men and 
DALYs were higher for ischaemic stroke than haem-
orrhagic stroke89,90. Data from the GBD study indicate 
that, although stroke- associated DALYs decreased in all 
regions of the world between 1990 and 2016, the region 
with the smallest reduction was sub- Saharan Africa2. 
According to the same data, 80% of all incident strokes, 
77% of all survivors of stroke, 87% of all deaths from 
stroke and 89% of all stroke- related DALYs occur in 
LMICs, including those in Africa91.
Quality of life and cost of care
Several studies have examined quality of life after stroke 
in Africa. The results of these studies consistently indi-
cated that survivors of stroke have poorer quality of life 
in multiple domains than stroke- free controls92,93. The 
most commonly reported predictors of quality of life 
were post- stroke disability, depression and stroke sever-
ity. The estimated cost of care per patient with stroke 
ranges from US$ 145 to US$ 4,860, depending on the 
care setting94. Cost of stroke care is higher in urban areas 
than in rural areas and higher in private health facili-
ties than in government health facilities94–98. Data from 
Africa have also identified a high burden of stroke on the 
psychological and emotional domains of quality of life 
of caregivers. Multiple studies have reported that female 
spouses are the predominant caregivers99–101; in a 2019 
study from Lagos, Nigeria, up to 86.7% of caregivers 
were women101.
Risk factors
Age is the major non- modifiable risk factor for stroke. 
A comparative, hospital- based study found mean age 
at stroke presentation to be at least 10 years lower in 
Indigenous Africans than in African Americans or 
Americans of European descent70, suggesting Africans 
are more likely to be affected by stroke during the the-
oretical peak of their vocational productivity. Similarly, 
another study found patients with stroke in Ibadan, 
Nigeria, to be younger than patients with stroke in 
Berlin, Germany70,102. Temporal trends from the GBD 
(1990–2016) study indicate that age- standardized 
stroke incidence is increasing in southern sub- Saharan 
Africa, suggesting a persistent burden of underlying 
stroke risk factors in this region2. Observations from 
the global INTERSTROKE study, which involved five 
African countries (Mozambique, Nigeria, South Africa, 
Sudan and Uganda) suggest that the profile of stroke 
risk factors is similar between Africa and the rest of the 
world, although regional differences in effect size exist103. 
This study identified ten top risk factors (hypertension, 
dyslipidaemia, diabetes mellitus, central obesity, cardiac 
causes, current smoking, high alcohol intake, unhealthy 
diet, physical inactivity and psychosocial factors) that 
accounted for 82% of the PAR for stroke among Africans 
and 92% of the PAR for stroke in the rest of the world103. 
The disparity could have resulted from an underesti-
mation of risk in Africa owing to a small dataset or to 
unexplained residual factors, such as infectious diseases, 
contributing to stroke risk. The Stroke Investigative 
Research and Educational Network Study (SIREN) is the 
largest multi- site case–control stroke risk factor study 
to be performed in Africa to date. The study included 
2,118 case–control pairs of Indigenous Africans from 
15 sites in Nigeria and Ghana104. Using rigorous case 
ascertainment methodology and a similar case mix as 
the INTERSTROKE study105,106, the SIREN study found 
that 98.2% (95% CI 97.2–99.0) of the adjusted PAR of 
stroke was associated with 11 potentially modifiable 
risk factors: hypertension, dyslipidaemia, regular meat 
intake, central obesity, diabetes mellitus, low consump-
tion of green leafy vegetables, stress, added salt at table, 
cardiac diseases, physical inactivity and current cigarette 
smoking104 (fig. 1).
Hypertension was the major modifiable risk factor 
identified by the INTERSTROKE study, with an odds 
ratio (OR) of 4.01 (99% CI 2.59–6.21) and PAR of 34.6 
(99% CI 30.4–39.1) for the African countries included 
in the study103. In the SIREN study, the OR and PAR 
for hypertension were even higher, at 19.36 (95% CI 
12.11–30.93) and 90.8% (95% CI 87.9–93.7), respec-
tively. The INTERSTROKE study had a smaller sample 
size of Africans and lower statistical power than the 
SIREN study, which could account for this disparity. 
Nevertheless, these data suggest that hypertension is 
the prime modifiable driver of the stroke burden in 
Africa, although many Africans also have other vascular 
co- morbidities that act in concert with hypertension to 
drive stroke burden. Indeed, >45% of people in Africa 
over 25 years of age are estimated to be hypertensive, 
which constitutes the highest burden of hypertension in 
the world, according to the WHO107. Evidence indicates 
that <50% of individuals with hypertension in Africa are 
aware that they have the condition or have received a 
diagnosis and, among those who are diagnosed, at least 
half are not receiving treatment108. Thus, strategies to 
reduce the impact of hypertension will greatly reduce 
the risk of strokes among Africans104,108,109. In contrast 
to non- African cohorts, atrial fibrillation has not been 
consistently reported as a substantial risk factor for 
strokes in Africa (it accounted for 7% of all strokes in 
the INTERSTROKE study), although this observation 
could be the result of under- reporting110.
A comparison between data from the SIREN 
study and data from the population- based Reasons 
for Geographic and Racial Differences in Stroke 
(REGARDS) cohort study of African Americans and 
Americans of European descent living in the USA found 
higher frequencies of several cardiometabolic factors 
(hypertension, diabetes mellitus and dyslipidaemia) 
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among Indigenous Africans and African Americans 
than in Americans of European descent70 (fig.  2). 
However, the comparison also identified a higher fre-
quency of several cardiac and lifestyle factors (smok-
ing, high alcohol intake and physical inactivity) among 
African Americans and Americans of European descent 
than among Indigenous Africans. These observations 
underscore the interaction between ethnic (includ-
ing genetic) and geographical (lifestyle) factors in the 
vascular pathophysiological cascade70,102.
Stroke with co- morbid conditions. In Africa, as elsewhere, 
strokes occur alongside other conditions. In particular, 
HIV infection increases the risk of stroke111,112. Africa 
bears the largest global burden of HIV infection — 70% 
of the 36.8 million people who were living with the 
virus in 2017 were located in sub- Saharan Africa113. 
Africans with HIV and stroke generally have a young 
age at stroke onset (<45 years), severe stroke presenta-
tion, preponderance of ischaemic strokes and advanced 
immunosuppression114–117. The results of a Tanzanian 
stroke incidence project, which involved community- 
ascertained controls, found HIV infection to be an 
independent risk factor for stroke, with an OR of 5.61 
(CI 2.41–31.09)53. Several mechanistic links between 
HIV infection and strokes have been suggested111, 
including clustering of cardiometabolic factors, inflam-
mation of the brain vascular endothelium, coagulation 
abnormalities, vasculitis, HIV- associated vasculopathy 
and dyslipidaemia owing to anti- retroviral therapies and 
insulin resistance. However, more studies are needed 
to unravel the epidemiological contribution of HIV 
infection to the burden of stroke in Africa118.
Africa bears the greatest burden of SCD in the world, 
as 75% of the >300,000 individuals born with SCD 
globally every year are born in sub- Saharan Africa119. 
SCD has been reported to increase stroke risk among 
children and adults in Africa120,121. There is a bimodal 
age distribution in the incidence of ischaemic stroke 
in individuals with SCD: most strokes occur before 
20 years and after 30 years of age, with peak inci-
dence at 10–15 years122,123. In a systematic review and 
meta- analysis involving 18,977 participants with SCD 
pooled from 23 African studies, the overall prevalence of 
stroke was 4.2%124. Stroke in individuals with SCD typi-
cally presents with transient ischaemic attacks, seizures 
and focal neurological deficits such as hemiparesis124. 
Cerebral ischaemia in SCD is thought to result from 
the occlusion of distal internal carotid arteries, middle 
cerebral arteries and anterior cerebral arteries120,121,123,124. 
Haemorrhagic strokes in SCD usually occur in the third 
decade of life121 and are associated with low steady- state 
haemoglobin levels and high steady- state leukocyte 
counts125. Emerging data from Kumasi, Ghana, indicate 
higher numbers of stroke admissions and stroke mor-
tality in January–June 2020 than in January–June 2019, 
suggesting a link between stroke risk and SARS- CoV-2 
infection126. SARS- CoV-2 infection has been associated 
with increased fibrin, D- dimers and hypercoagulability, 
indicating that infection will increase the likelihood of 
strokes in vulnerable Africans with pre- existing vascular 
risk factors127.
Drivers of the rising burden of stroke in Africa. Data 
accrued over the past two decades and modelling esti-
mates from the GBD study suggest a progressive increase 
in the burden of stroke in Africa4,128. Indeed, stroke 
and its risk factors (cardiovascular diseases) are now 
the leading cause of death of the adult population in the 
continent129. The drivers of this increasing stroke burden 































































































































































































Risk factors Risk factors
Fig. 1 | Risk factors for stroke in Africa. a | The population attributable risk associated with 10 potentially modifiable risk 
factors in the INTERSTROKE study (Africa sub- cohort). The study included 973 case–control pairs of Indigenous Africans 
from sites in Mozambique, Nigeria, Sudan, South Africa and Uganda. Data from ref.103 and ref.105. b | The population 
attributable risk associated with 11 potentially modifiable risk factors in the Stroke Investigative Research and Educational 
Network (SIREN) study. The study included 2,118 case–control pairs of Indigenous Africans from multiple sites across Nigeria 
and Ghana. Data from ref.104.
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in Africa can be categorized into early- life, mid- life and 
late- life factors (fig. 3). Early- life factors, including fetal 
and/or infant undernutrition and low birth weight, have 
been associated with cardiometabolic disorders such as 
high blood pressure, dysglycaemia and dyslipidaemia 
later in life15,17,130. This link is thought to be the result 
of fetal reprogramming and epigenetic changes. A good 
illustration of the delayed effects of early- life under-
nutrition is the high burden of hypertension, diabetes 
and overweight status reported among survivors of the 
Nigerian civil war (the Biafran War), which occurred in 
the late 1960s16. Many of these individuals were exposed 
to severe famine in early life as a result of the conflict.
Early- life undernutrition might also partly explain 
the increased risk of cardiometabolic disorders among 
individuals who grow up in low- income rural areas but 
migrate to urban areas131. As these individuals approach 
mid- life with increasing wealth, they adopt lifestyles 
associated with urban living. Such lifestyles are often 
characterized by low levels of physical activity, high 
caloric intake, smoking, high levels of alcohol con-
sumption, high intake of meat and low consumption 
of green leafy vegetables. Evidence indicates that expo-
sure to stress and air pollution further exacerbates the 
course of neurovascular disease through the promotion 
of neuroinflammation and endothelial dysfunction18,132. 
Indeed, neither urban nor rural Africa is spared from 
the emerging risks of stress and air pollution (indoor air 
pollution from solid fuels and outdoor ambient partic-
ulate matter pollution) and both are likely to contribute 
to the increases in stroke incidence that we are observ-
ing in Africa19. The GBD 2013 study identified a sub-
stantial contribution of household air pollution to the 
risk of stroke in LMICs, with the largest household air 
pollution- associated risk observed in the West African 
sub- region128.
Late- life factors driving the increasing burden of 
stroke in Africa include a progressive increase in life 
expectancy, which is resulting in population ageing133. 
Multiple cohort and population- based studies in Africa 
have identified ageing as a key non- modifiable risk fac-
tor for stroke, indicating that an increase in the num-
ber of older people in the population will result in an 
increase in stroke burden4,12. Genetic predisposition to 
stroke and stroke- related epigenetic modifications oper-
ate across the life course. For example, an association has 
been found between IL6 rs1800796 and ischaemic stroke 
among West Africans134. The observation that fine par-
ticulate matter air pollution is associated with elevated 
plasma levels of IL-6 (ref.135) strengthens the possible link 
between air pollution and the increasing stroke burden.
Another contributor to the increasing burden of 
stroke in Africa is the limited availability of medication 
to control the more common risk factors. Drugs for 
the treatment of hypertension and diabetes are costly 
and might not be readily available in most health sys-
tems in Africa136. Furthermore, the vast majority of 
African countries do not have health insurance sys-
tems that can pay for the medications in full or even 
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Fig. 2 | Effect of race and geography on risk factors for stroke. Graph shows the frequency of eight risk factors in 
Indigenous Africans, African Americans and Americans of European descent. Study participants were >55 years of age. 
The data for this analysis came from 1,928 individuals with stroke who met the selection criteria and consisted of 811 
Indigenous Africans recruited into the Stroke Investigative Research and Educational Network (SIREN) study, 452 African 
Americans and 665 Americans of European descent who were participants in the Reasons for Geographic and Racial 
Differences in Stroke (REGARDS) study. The group of participants of African ancestry had a significantly higher prevalence 
of hypertension and diabetes, similar frequency of dyslipidaemia and lower prevalence of cardiac disorders than Americans of  
European descent. However, obesity and lifestyle factors, including smoking, alcohol consumption and physical inactivity, 
were more prevalent among African Americans and Americans of European descent than Indigenous Africans. These data 
illustrate the complex interaction between racial (genetic) and geographical (environmental, for example, lifestyle) factors 
in the neurobiology of stroke. Data from ref.70.
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treatment is a substantial economic load on the patient 
and their family. Poor health literacy can also contri-
bute to a lack of control of vascular risk factors139,140. 
In the PURE study, which involved >150,000 partici-
pants from urban and rural settings around the world, 
<10% of participants from low- income countries with 
a previous cardiac or stroke event were on any of the 
four drugs indicated for secondary prevention, that is, 
angiotensin- converting enzyme inhibitors, beta block-
ers, statins or aspirin141. In a study performed in the 
Southwest region of Cameroon, essential cardiovascular 
disease medicines were only available in 25.3% of public 
pharmacies and 49.2% of community pharmacies136. 
Medicines for heart failure and dyslipidaemia, including 
beta blockers, angiotensin- converting enzyme inhibitors 
and statins, cost the equivalent of 2–13 days’ wages for 
a 1- month supply.
Stroke phenotypes in Africa
Information on the phenotypic characteristics of stroke 
types and subtypes in Africa was limited until evidence 
from the SIREN study became available in early 2018. 
In the initial data from this study, which recruited index 
stroke cases from 15 sites in Nigeria and Ghana, of 
2,118 individuals with neuroradiologically confirmed 
stroke, 68% had ischaemic stroke, 32% had intracere-
bral haemorrhage (ICH) and <1% had ischaemic stroke 
with haemorrhagic transformation104. The SIREN inves-
tigators did not recruit participants with sub- arachnoid 
haemorrhage but it is estimated to contribute to ~5% of 
all strokes in Africa142.
Ischaemic stroke
In Africa, the most common aetiological subtype of 
ischaemic stroke is small vessel disease (SVD) (42%), 
followed by large vessel atherosclerotic disease (17%), 
cardioembolism (11%) and undetermined (30%)70,104. 
In a meta- analysis of five different stroke studies involv-
ing a total of 2,843 participants with ischaemic stroke 
from both hospital and community- based cohorts in 
Ghana, Kenya, Nigeria, Mozambique, South Africa, 
Sudan and Uganda, we found that SVD accounted for 
30% of ischaemic strokes12. By contrast, SVD accounted 
for only 19% of ischaemic strokes from 13 different 
studies involving 12,931 patients from hospital and 
non- hospital or community- based cohorts in western 
Europe and the USA12. The preponderance of SVD and 
the relative paucity of cardioembolic strokes among 
Africans is similar to observations from other LMICs 
such as China143 and Pakistan144 but in contrast to data 
from high- income countries. Indeed, studies conducted 
in mixed ethnic populations in the USA145 and the UK146 
strongly suggest that SVD is twice as common among 
participants of African descent than among participants 
of European descent. Participants of European descent 
were more likely than participants of African descent to 
have a cardioembolic or large- artery atherosclerotic 
stroke.
The above observations indicate that the relative fre-
quencies of ischaemic stroke subtypes across the globe 
vary by race, geography and, perhaps, gross national 
income. Therefore, association studies on the genetics 
of ischaemic stroke among Indigenous Africans are 
eagerly awaited. However, it seems likely that the high 
burden of undiagnosed and uncontrolled asymptomatic 
risk factors (notably hypertension, dyslipidaemia and 
dysglycaemia) in sub-Saharan Africa is leading to arterio-
losclerosis and microatheroma formation in deep per-
forating cerebral vessels and thus causing SVD-related 
ischaemic strokes12. This hypothesis is consistent with 
the observation that, among Africans, hypertensive 
disease is more prevalent than atrial fibrillation or 
atherosclerotic disease (discussed above). Indeed, few 
studies have researched cervicocephalic atherosclerosis, 
a marker of epidemiological and stroke transition, among 
Africans147. Neurovascular ultrasonography detected no 
substantial carotid artery disease in the Tanzania Stroke 
Incidence Study148. However, a study in participants with 
hypertension and stroke in Nigeria found that carotid 
intima media thickness was a sensitive indicator of 
cardio vascular phenotype and had a stronger association 
with stroke than popular cardiovascular risk calculators 
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Fig. 3 | A life course approach to factors driving stroke burden in Africa. The population- level risk factors for stroke 
change across the lifespan. Here, we summarize the risk factors at each stage of the life course that are driving the 
increasing burden of stroke in Africa. We also highlight the molecular mechanisms and processes involved in stroke risk  
at each stage of life. HIV, human immunodeficiency virus.
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that are used to estimate the time- related risk of cardio-
vascular disease149,150. A more recent study of individuals 
diagnosed with acute stroke- like syndrome in Malawi 
reported that 39.4% had extracranial atherosclerosis and 
19.2% had intracranial atherosclerosis151. Post- mortem 
studies undertaken ~40 years apart also identified a tem-
poral increase in the frequency and severity of cerebral 
atherosclerosis among Nigerian Africans in tandem with 
the overall rise in the burden of cardiovascular disease 
and stroke occurrence152–154.
Intracerebral haemorrhage
Further evidence of poor blood pressure control in 
sub- Saharan Africa has been gleaned from the aetiolog-
ical profile of ICH. In the SIREN study, the aetiology of 
ICH was classified using the structural lesion, medica-
tion, amyloid angiopathy, systemic and/or other disease, 
hypertension, undetermined (SMASH- U) algorithm155. 
Using this method, the most common aetiology was 
hypertension (80.9%); less common were structural 
vascular anomalies (4.0%), cerebral amyloid angiopathy 
(0.7%), systemic illnesses (0.5%) and medication- related 
aetiologies (0.4%)156. Aetiology remained undetermined 
in 13.7% of participants. Of considerable interest is the 
observation that, among West Africans, ICH consti-
tutes 53% of all strokes occurring among the young 
(<50 years of age)156. The six factors most associated 
with stroke in the young (who constituted 25% of the 
SIREN cohort) were hypertension, dyslipidaemia, diabe-
tes mellitus, low consumption of green leafy vegetables, 
psychosocial stress and cardiac disease157. These further 
underscore the observation that hypertension is more 
strongly associated with ICH than ischaemic stroke103,104 
and thus emphasize that large numbers of strokes, par-
ticularly among young Africans, could be avoided by 
better blood pressure control. The PAR of stroke result-
ing from hypertension in the SIREN study was 88.7% 
among young West Africans157, again highlighting the 
importance of this vascular risk factor. Furthermore, in 
a recent cross- sectional study in Ghana, the frequency of 
refractory hypertension (a rare and severe phenotype 
of treatment- resistant hypertension) among ~1,200 sur-
vivors of stroke was 5.8% compared with 0.7% among 
~2,800 stroke- free individuals with hypertension158. 
The prevalence of refractory hypertension was much 
higher in individuals <60 years of age than in indi-
viduals >60 years of age. The odds ratios of refractory 
hypertension were 13.6 for lacunar stroke, 11.4 for ICH 
and 3.7 for non- lacunar ischaemic strokes relative to 
stroke- free hypertension. This further suggests that the 
phenotypic characteristics of hypertension also exert 
differential effects on the manifestation of stroke types. 
Further studies are now required to elucidate the mech-
anisms underlying these differences and to guide the 
design of targeted population- level interventions and 
risk- reduction strategies.
Stroke complications and sequelae
Stroke complications include a range of neurologi-
cal, psychiatric or other systemic manifestations that 
occur in the acute, subacute or chronic phases of a 
stroke. Most data on stroke complications in Africa 
come from hospital- based studies and suggest that 
some form of complication occurs in >80% of inpa-
tients with stroke (Table 2). Stroke complications in 
Africa include delirium159–161, post- stroke aspiration 
pneumonia85,86,162–166, bacteriuria and urinary tract 
infection167–169, aphasia and deglutition disorders170, 
anxiety99,171–173, fatigue174–176, sexual dysfunction177–179, 
pain (central post- stroke pain syndrome)180–183, depres-
sive illness184–193 and cognitive impairment that often 
leads to dementia194–197.
On average, 40–50% of survivors of stroke in Africa 
develop some form of cognitive dysfunction194,196, sug-
gesting that vascular cognitive impairment could become 
the most common precursor to dementia in Africa. 
Several hospital- based studies have investigated the prev-
alence of post- stroke seizures in Africa. The prevalence 
of early (≤7 days of stroke onset) post- stroke seizures 
were 9.3%198, 9.6%199 and 13%200 in the three studies that 
recorded this data. The prevalence of epilepsy among 
survivors of stroke in Africa was 1.98–16.9%201–204 
(Table 3). Factors associated with an increased risk of 
post- stroke epilepsy included male sex, cortical infarcts 
and poor access to neurological services. However, the 
results of these studies need to be interpreted in the con-
text of variation in study methods and case definition 
and the potential inaccuracy of patient reports owing to 
the cultural stigma around epilepsy in Africa.
In several studies, the functional outcomes in patients 
with stroke in Africa were carefully monitored using 
established scales43,50,205–214 (Table 4). The results of these 
studies suggest that there is a substantial post- stroke 
disease burden that needs attention. Evidence from the 
few available studies in Africa suggests that survivors of 
stroke are likely to return to work after the first year215,216. 
Shorter post- stroke duration, lower functional independ-
ence and worse post- stroke cognitive dysfunction were 
associated with a lower likelihood of a return to work.
Genetics of stroke in Africa
Evidence indicates that, compared with populations 
of European descent, stroke in the Indigenous African 
population has an earlier age of onset and is more likely 
to be haemorrhagic or SVD- related ischaemic4,23,70,102. 
Differences in stroke severity and outcomes have also 
been observed between Indigenous Africans and popu-
lations of European descent. Broad differences in the 
demographic structures of the African population and 
populations in Europe and the USA as well as differences 
in the availability of health services offer plausible expla-
nations for these disparities217. Nevertheless, a possible 
role of genetic and/or epigenetic factors warrants further 
exploration23,24. For example, differences between chron-
ological age and biological age (which is determined on 
the basis of epigenetic changes) have been documented 
among individuals of European ancestry with stroke218 
and whether a similar phenomenon occurs among 
African individuals needs to be explored219. Higher 
stroke heritability among individuals of African ancestry 
than among individuals of European ancestry has been 
reported in the South London Stroke Registry220 but the 
exact effect of this heritability requires in- depth studies 
in Indigenous African populations.
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Genomic diversity in Africa
Africa is regarded as the cradle of modern humans, 
Homo sapiens, and African genomes are more diverse 
than those from any other continent221–223; however, 
only a fraction of the genetic diversity among African 
individuals has been surveyed — to date, <2% of GWAS 
were performed on African data224. In a high- depth 
study of African genomes, whole- genome sequencing 
was performed on samples from 426 individuals from 
50 ethnolinguistic groups; the genetic makeup of many 
of these groups had not been previously studied225. The 
results of this study, published in 2020, identified more 
than 3 million previously undescribed genetic variants. 
The implications of the identification of these variants 
for our understanding of the genetics of the stroke phe-
nome are immense and are relevant to both Africans 
and the global population25,226. In particular, the Human 
Heredity and Health in Africa Initiative222 is facilitating 
the genetic exploration of African populations, includ-
ing the SIREN study cohort, by use of approaches 
including candidate gene studies and GWAS23,24. The 
overall aim is that inclusion of Indigenous Africans in 
multi- ethnic genomic studies, combined with the use of 
trans- omics approaches, will facilitate genetic fine map-
ping, trans- ancestry meta- analysis and development of 
ancestry- sensitive polygenic risk scores as well as the 
discovery of new risk loci, pathophysiological path-
ways, biomarkers and drug targets for the enhancement 
of precision stroke medicine24,25,226,227.
Candidate gene studies and GWAS
To date, the majority of genetic studies of stroke in 
Africa have adopted a candidate gene approach (Table 5). 
Candidate gene studies and GWAS are two methods that 
are used to detect genetic susceptibility to diseases. The 
main difference between the two approaches is that can-
didate gene studies investigate genetic variation within a 
small number of pre- identified genes of interest, whereas 
in GWAS, the entire genome is investigated for common 
genetic variations that are associated with the disease 
of interest. In northern Africa, candidate gene studies 
have reported associations between stroke, particularly 
ischaemic stroke, and polymorphisms in multiple genes, 
including those encoding apolipoprotein E (APOE), 
IL-1, IL-1β, peroxisome proliferator- activated receptor- δ 
(PPARD), apolipoprotein A5 (APOA5) and aldosterone 
synthase (CYB11B2)228–242. In addition, a polymorphism 
in the gene encoding angiotensinogen (AGT) was associ-
ated with stroke in an Egyptian cohort consisting of ado-
lescents with SCD243. A candidate gene study performed 







Delirium Onset 1 week after 
stroke; confusional 
states
32–33 Age, NIHSS score Nigeria 159–161
Aspiration 
pneumonia
Cause of death after 
stroke
64–79 Age, stroke severity, 
consciousness












Aphasia can last for 
up to 60 months after 
stroke
~50 Age, left- hemispheric stroke, 
cognitive impairment
Tanzania 170
Anxiety Accumulative over  
12 months





Fatigue Peak at 6 months after 
stroke
60 Poor quality of life Ghana, Nigeria 174–176
Sexual 
dysfunction
Most common: erectile 
dysfunction and low 
libido
>80 Age, male sex Nigeria 177–179
Pain Usually musculoskeletal 
pain or central post- stroke 
pain syndrome
5–80 Background history of pain, 
differential thresholds, age at 
stroke onset
Nigeria, Zimbabwe 180–183





Age Democratic Republic 







30–50 Age, low literacy, vascular risk 
factors, Black race, recent 
infection, MTLA, WMH
Ghana, Nigeria, South 
Africa
194–197
On the basis of data from hospital- based studies. For details on post- stroke epilepsy and functional disability, see Tables 3 and 4. 
CFU, colony- forming unit; MTLA, medial temporal lobe atrophy; NIHSS, National Institutes of Health Stroke Scale; WMH, white 
matter hyperintensities. aPercentage of individuals with stroke who go on to develop these complications.
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in Zambia identified an association between APOEε2/ε4 
genotype and an increased risk of both haemorrhagic 
and ischaemic stroke244. Findings from the West African 
SIREN study included a significant association of var-
iants on IL6 and CDKN2A/2B with risk of ischaemic 
stroke among men134 as well as a significant association 
of variants on APOL1, CDKN2A/2B and HDAC9 with 
risk of SVD ischaemic stroke245. This study was the first 
to identify a stroke- related variant on APOL1, although 
the gene had previously been associated with chronic 
kidney disease in individuals of African descent246,247. 
A particularly intriguing observation is that, whereas 
APOE alleles influenced the risk of stroke in northern 
and southern Africa, an APOLI risk variant was associ-
ated with stroke in western sub- Saharan Africa. Further 
studies are needed to explore the potential geographical 
disparity in the effect of these two prominent apolipo-
protein genes; the results of such studies could also be 
relevant to other brain disorders such as Alzheimer dis-
ease. The first stroke GWAS in Africa is currently under 
way and is anticipated to provide further insight into the 
genetic architecture of stroke in Indigenous Africans by 
identifying novel stroke- associated variants.
Stroke services in Africa
Stroke services are organized systems and structures 
for delivering preventive, therapeutic and rehabilita-
tive stroke care at an institutional, regional or national 
level. The World Bank’s Disease Control Priorities 3rd 
edition248 identified five major platforms for the provi-
sion of essential universal health coverage in LMICs: 
population- level platforms, community- level plat-
forms, health centres, first- level hospitals and referral 
hospitals. These platforms provide a model for building 
chains of stroke care that can be divided into three cate-
gories: pre- hospital, hospital and post- hospital services. 
Pre- hospital stroke services consist of elemental and 
primary prevention policies, surveillance, pre- hospital 
emergency care, and outreach and awareness services. 
Hospital- based stroke services include emergency 
medical services, acute stroke treatments, secondary 
prevention and acute rehabilitation. Post- hospital stroke 
services consist of community rehabilitation, social and 
family support, and follow- up.
Population- based services
Stroke shares a common risk- factor profile with 
many cardiovascular diseases; thus, population- based 
approaches to stroke prevention in Africa have con-
ventionally focused on non- communicable diseases 
as a whole. In 2015, non- communicable diseases were 
incorporated into the United Nations Sustainable 
Development Goals: target 3.4 is “By 2030, to reduce by 
one third premature mortality from non- communicable 
diseases through prevention and treatment and to 
promote mental health and well- being”249. However, 
progress reports from Africa published in 2017–2020 
suggest low levels of progress towards this target as 
a result of a lack of political will, poor intersectoral 
collaboration, absence of universal health coverage, 
widespread poverty, the challenges involved in mak-
ing changes to existing health systems and low levels 
of public spending on health250–252. The joint World 
Stroke Organization (WSO)–WHO–Lancet Neurology 
Commission for Stroke is advocating pragmatic, context- 
sensitive approaches that involve multiple stakeholders, 
including healthcare providers, physicians, patients, 
the general population, policy- makers and payers, with the 
aim of identifying solutions that will enhance stroke 
prevention and surveillance services across a range of 
income levels253.
Pre- hospital acute stroke care
Pre- hospital acute stroke services conventionally 
function within existing emergency medical ser-
vices, although they can also be standalone services. 
Emergency medical services are poorly developed 
in Africa, except in some areas in South Africa and 
northern Africa that have a relatively higher income. 
In a recent survey, established emergency medical 
services were identified in only 16 African countries; 
most of the identified services were government oper-
ated, had fee- for- service payment structures and poor 
uptake254. Organizations such as the African Federation 
of Emergency Medicine have developed processes and 
guidelines for emergency medicine training in Africa, 
raising hopes of improving access to quality and effective 
emergency care; however, organizational, fiscal and 
regu latory challenges remain255,256. Few studies have 
examined the specific factors responsible for pre- hospital 
delays in stroke presentation in Africa; however, the 
available evidence suggests that poor stroke knowledge 
is a major cause of pre- hospital delays in presenta-
tion and poor outcomes257. Other contributing factors 
include stroke onset during normal sleeping hours, 
transportation- related delays, poor availability or a lack 
of ambulance services, absence of trained first respond-
ers and a paucity of neuroimaging services88,258–260. 
Evidence from a 2015 geospatial analytic study indicated 
that, for 71% of Africans, travel time to the nearest hos-
pital is >2 hours261, highlighting a dire need for broad 
intersectoral strategies to improve access to healthcare.
Table 3 | Estimated prevalence of post- stroke epilepsy in Africa
Country Year Study type Sample 
size
Diagnostic criteria Prevalence 
(%)a
Ref.
Burkina Faso 2006–2014 Hospital based; retrospective 1,616 Clinical, EEG, brain CT 1.98 201
Sudan 2006–2008 Hospital based 165 Clinical, eye- witness 
reports, EEG, brain CT
16.90 202
Benin 2015–2016 Hospital based; retrospective 1,703 Clinical, EEG, brain CT 2.00 203
Ghana 2018–2020 Hospital based; cross- sectional 1,101 Clinical, brain CT, EEG 11.40 204
aPercentage of individuals with stroke who go on to develop post- stroke epilepsy.
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Onset- to- door or onset- to- needle time is often 
used as an indicator of timeliness of stroke triage and 
efficiency of acute reperfusion therapy. Evidence from 
the European Safe Implementation of Thrombolysis 
in Stroke- Monitoring Study (SITS MOST) and Safe 
Implementation of Treatments in Stroke–Eastern 
Europe (SITS EAST)262 study indicates a median 
onset- to- door time of 140 minutes. Similarly, data from 
the American Get With The Guidelines – Stroke registry 
(GWTG- Stroke)263 indicate a median onset- to- door time 
of 144 minutes. Indeed, the paradigm of acute stroke 
care in high- income countries currently emphasizes 
ultra- early pre- hospital stroke diagnosis, treatment 
using mobile stroke units and telemedicine for stroke 
assessments264,265. By contrast, a systematic review of 
studies from Africa found a median time from stroke 
onset to hospital admission of 31 hours266. In a single 
hospital study from Burkina Faso, median stroke onset 
to hospital admission time was ~7 hours but only 19% of 
patients presented within 4.5 hours of stroke onset and 
were thus eligible for thrombolysis267.
Hospital- based acute stroke care
The profile, pattern and quality of hospital- based acute 
stroke care in Africa is heterogeneous. Services for stroke 
often exist as part of general medical services, although 
stroke units have now been reported in at least ten 
countries, including Morocco, Tunisia, Algeria, Egypt, 
Mauritania, Ghana, Nigeria, Guinea, Central African 
Republic and South Africa3,268,269. In addition, acute 
stroke services do exist in private hospitals in some parts 
of Africa.
The WSO has produced the global stroke ser-
vices guidelines and action plan270 as a framework to 
guide the development of stroke services around the 
world. The framework proposes three tiers of stroke 
services (minimal, essential and advanced), depend-
ing on the availability of multidisciplinary expertise, 
diagnostic infrastructure and capacity for acute reper-
fusion therapy. The applicability and effectiveness of 
this framework in low- resource African settings were 
recently demonstrated in Conakry, Guinea, where a 
minimal stroke unit was set up. This unit consisted of 
a dedicated space equipped with three acute beds, heart 
rate, blood pressure and blood oxygen saturation mon-
itoring equipment, and a portable oxygen concentrator. 
Patient outcomes 1 year after establishment of the unit 
were better than patient outcomes 1 year before the 
unit was established; introduction of the stroke unit 
was associated with lower mortality (7.2 versus 22.3%; 
P < 0.0001), fewer medical complications (4.1 versus 27.7%; 
P < 0.001) and a lower rate of pneumonia (3.3 versus 
14.5%; P < 0.001)268.
Similarly, the introduction of multidisciplinary stroke 
care in a South African secondary- level hospital was 
associated with a substantial reduction in in- hospital 
mortality and improved uptake of neuroimaging271. 
Neuroimaging services (CT or MRI) are essential for 
the accurate diagnosis of stroke but the availability, 
accessibility and affordability of these services are lim-
ited in many African settings88,259,260. The SIREN Study 
Team developed a novel computer software application 
— the AIM on ClearCanvas Enriched Stroke phenotyp-
ing Software (ACCESS) — that enables the creation of 
Table 4 | Estimated frequency of functional disability after stroke in Africa




Sample size Tools used Percentage 
with disability
Ref.
Gambia (Banjul) 1990–1991 Hospital Not stated 106 Barthel Index 91.5 at 1 month 
after stroke
205




108 Barthel Index 60 43
South Africa 
(Cape Town)
2004–2006 Hospital 4,524,335 196 MRS, Barthel 
Index










Not known Hospital and 
community
Not stated 68 Barthel Index 47 at discharge; 





2010 Hospital Not stated 67 Barthel Index 81.82 at 
discharge
208
Nigeria (Ibadan) 2013 Hospital Not stated 128 MRS 60.9 209
Benin (Parakou) 2013 Hospital Not stated 85 MRS 53 at 1 month 
after stroke
210
Nigeria (Benin) Not known Hospital and 
outpatient
Not stated 102 MRS 71.6 211
Uganda 
(Kampala)
2014 Hospital Not stated 127 Barthel Index 46.1 at 1 month 
after stroke
212
Egypt (Cairo) 2015–2016 Hospital Not stated 397 MRS 18 213
Egypt (Cairo) 2018–2019 Hospital Not stated 61 (posterior 
circulation stroke)
MRS 72.13 at 3 months 
after stroke
214
FIM, functional independence measure; MADRS, Montgomery–Asberg depression rating scale; MRS, modified Rankin score.
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simple, standardized annotations for the reporting of 
brain images of all stroke types. The software enabled 
concordant and reproducible classification of stroke 
subtypes by multiple investigators, making it suitable for 
routine clinical use and multicentre research272.
The availability of and access to acute reperfusion 
therapies in Africa are currently limited but growing. 
These therapies are now available in Morocco, Tunisia, 
Algeria, Egypt, Central African Republic and South 
Africa88,269,273–276. Barriers to access include all causes 
of late hospital presentation, diagnostic delays, the 
high cost of thrombolytic agents and insufficient num-
bers of clinicians with the appropriate skills88,275,277,278. 
Early reports from the countries listed above have 
consistently shown that intravenous thrombolysis is 
associated with improved patient outcomes269,273,274,276. 
Door- to- needle times were between 54 and 160 min-
utes and ≤5% of patients developed spontaneous ICH 
complications269,273,276. Two prospective observational 
studies conducted at the Ain Shams University hospi-
tals in Egypt reported remarkable success in overcoming 
barriers to thrombolysis. Implementation of a compre-
hensive action plan — including government funding 
of alteplase (tPA) treatment and the introduction of 
needs- based training programmes for stroke care nurses, 
doctors and emergency physicians — was associated 
Table 5 | Stroke candidate gene studies in Africa





Plasminogen activator inhibitor 1  
(PAI1); tissue plasminogen 
activator (tPA)
Tunisian PAI1 4G/5G polymorphism associated with 
increased PAI1 expression, decreased tPA 
expression and increased risk of stroke
Saidi​et al.​
(2007)233
Apolipoprotein E (APOE) Tunisian APOE ε4 associated with increased risk of ischaemic 
stroke, small vessel disease and statin use
Saidi​et al.​
(2008)230
Human platelet alloantigen 1–5 
(HPA1–5)
Tunisian Lower HPA1a frequency and higher HPA1b 
frequency in the stroke group than in controls
Saidi​et al.​
(2008)229
HPA1–5 Tunisian HPA1a/b and HPA5a/b alleles associated with 
increased risk of stroke; HPA1b/b and HPA5b/b 




APOE; angiotensin- converting 
enzyme (ACE)
Tunisian Higher APOEε4 frequency and lower APOEε3 
frequency in the stroke group than in controls; 
APOε4 ACE Del/Del genotype was associated with 
large vessel stroke and was detected in higher 
proportions in older (>50 years) patients
Saidi​et al.​
(2009)231
Angiotensinogen (AGT) Tunisian Multiple AGT polymorphisms were significantly 
associated with an increased risk of stroke
Saidi​et al.​
(2010)228
Aldosterone synthase (CYP11B2) Tunisian CYP11B2 C-344T polymorphisms (T allele bearing) 
were associated with risk of ischaemic stroke
Chehaibi​et al.​
(2013)236
Peroxisome proliferator- activated 
receptor- δ (PPARD)
Tunisian PPARD +294T/C polymorphism was associated 





Tunisian MTHFR C677T and A1298 polymorphisms were 
associated with an increased risk of ischaemic stroke
Atadzhanov 
et al.​(2013)244
APOE Zambian APOEε2/ε4 genotype associated with increased 




Matrix metalloproteinase 1 
(MMP1) and MMP12
Tunisian MMP12 polymorphisms were associated with an 








eNOS Moroccan eNOS G894T polymorphism was associated with 
risk of ischaemic stroke
Rezk​et al.​
(2015)242
IL-1 cluster genes: IL1B, IL1A and 
IL1RN
Egyptian IL1B −511 and IL1A −889 polymorphisms were 




5- lipoxygenase- activating 
protein (ALOX5AP)
Moroccan APOA5 T1131C and ALOX5AP SG13S114 









IL6 rs1800796 and CDKN2A/2B rs2383207 are 
associated with risk of ischaemic stroke in men
Akinyemi​et al.​
(2018)245
Apolipoprotein 1 (APOL1); 





APOL1 rs73885319, CDKN2A/2B rs2383207 and 
HDAC9 rs2107595 are associated with risk of small 
vessel disease ischaemic stroke
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with an increase in the proportion of patients eligible 
for intravenous thrombolysis from 13.2% to 94.3%276.
Strong leadership, improved governmental funding, 
enhanced stroke awareness, training and partnerships 
have been reported as factors that have remarkably 
transformed acute stroke care in the northern African 
and Middle East region269,279. Over a 5- year period, the 
region recorded a dramatic increase in the number of 
stroke units, multidisciplinary stroke specialists and 
centres with capacity for acute reperfusion therapy279. 
Widespread uptake of the Safe Implementation of 
Treatments in Stroke (SITS) registry and partner-
ship with the Angels Initiative of the European Stroke 
Organization has resulted in a remarkable transforma-
tion of the acute stroke care landscape in North Africa269. 
The lessons from this impressive success story can be 
deployed and adapted across other African regions.
Stroke rehabilitation services
Stroke rehabilitation is an important component 
of stroke care. However, the layout, referral pathways, 
extent of integration into stroke units or stroke multi-
disciplinary teams, and the time spent on rehabilitation 
varies widely across Africa. Ideally, stroke rehabilita-
tion should start as soon as possible after a stroke, pre-
ferably within a stroke unit, with the aim of achieving 
early mobilization in order to reduce complications. 
However, studies of rehabilitation in African stroke units 
are scarce. Furthermore, the numbers of stroke rehabili-
tation professionals, including physiotherapists, occu-
pational therapists, and speech and language therapists, 
seem to be insufficient280. In 2017, the WHO launched 
‘Rehabilitation 2030: a call for action’281, which highlights 
the need for all countries to scale up rehabilitation ser-
vices and support the use of health information systems 
to improve patient follow- up for rehabilitation both 
within hospitals and in the community.
Daily experience from our stroke care practice in 
Africa suggests that rehabilitation commonly begins 
soon after admission and is usually supervised by 
physiotherapists, who are supported by occupational 
therapists, speech therapists and social workers. Stroke 
rehabilitation in Africa often occurs in the general 
medical setting and is provided by professionals who 
also see patients with other conditions. A review pub-
lished in 2020 identified poor physician knowledge of 
the role of rehabilitation, lack of rehabilitation compo-
nents in the standard of care, long interval from stroke 
onset to rehabilitation, short duration of rehabilitation 
and poor financial support of rehabilitation services as 
inherent problems in the rehabilitation landscape in 
Africa280. Given these challenges, the responsibility of 
post- discharge rehabilitative care of patients with stroke 
falls on family members and caregivers. Task shifting 
and tele- health approaches have been suggested as 
strategies to mitigate the current scarcity of rehabilita-
tion personnel and improve access to stroke rehabili-
tation in Africa281–283. A study of family- led rehabilitation 
after stroke (the ATTEND trial) was performed in India 
and this option could also be explored in Africa277,284. 
In a prospective, single- arm, pre–post study, 20 survi-
vors of stroke recruited from a tertiary medical centre 
in Ghana received a smartphone with the 9zest Stroke 
Rehabilitation Therapy app (9zest) to deliver an indi-
vidualized, goal- targeted exercise programme 5 days 
a week. Rehabilitation was remotely supervised by a 
tele- therapist for 12 weeks. The study demonstrated the 
feasibility of administering a mobile health- delivered 
physical therapy intervention in sub- Saharan Africa, 
with high user satisfaction285. Ongoing studies include 
the MAMBO (Measuring Ambulation, Motor, and 
Behavioural Outcomes with post- stroke fluoxetine in 
Tanzania), which aims to determine the safety and effi-
cacy of fluoxetine among Africans with acute stroke and 
to establish whether the treatment is associated with any 
improvement in motor outcomes286.
Stroke support and community outreach
Stroke support and community outreach can be achieved 
through direct and indirect services. In Africa, direct 
stroke support and community outreach are primarily 
offered by non- governmental organizations (NGOs) 
or agencies. National departments of health are yet to 
invest sufficiently in the detection, treatment and care 
of non- communicable diseases (including strokes). 
NGOs face funding challenges that affect their capac-
ity to support patients with stroke and their families. 
Although stroke support services and community out-
reach seem to have attained some visibility across Africa 
as a whole within the past decade, in large parts of the 
continent, these services do not meet the criteria for 
universal health coverage. The type of stroke support 
available varies across Africa. Direct services can include 
home- based care, patient- focused groups and some 
form of rehabilitation. Indirect services can include 
telephone support, including emotional support, for 
the patient with stroke and concerned family members. 
In addition, many NGOs conduct community- based 
health- risk assessments to identify individuals with a 
level of cumulative risk that qualifies them for referral 
to medical facilities. Hypertension, in particular, is the 
focus of many stroke- prevention community outreach 
programmes108.
Stroke knowledge and perception
A number of quantitative surveys and qualitative studies 
have explored stroke knowledge and perception among 
diverse groups of people in Africa and have revealed 
largely suboptimal awareness and perceptions that 
are influenced by religious and cultural beliefs287–289. 
Therefore, community leaders and leaders of faith- based 
organizations have a vital role in disseminating stroke 
knowledge across Africa. The percentage of participants 
who did not recognize the brain as the organ in which 
stroke occurs varied between 16.9% in a sample of hos-
pital workers and 85.9% in another sample of urban 
dwellers287,289,290. Hypertension and stress were most 
commonly identified as stroke risk factors and educa-
tional attainment was the most common determinant of 
stroke knowledge287,291. Among non- neurologist health 
workers292 and adolescent students293, stroke- based edu-
cational interventions were associated with substantial 
improvement in stroke literacy. We have also previously 
shown the feasibility of an educational mobile phone 
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short messaging service (SMS) including information 
on stroke for the control of blood pressure among West 
African survivors of stroke294,295. Across multiple sites 
in Nigeria and Ghana, treatment choices were found 
to be influenced by beliefs about stroke causation, and 
the development of culturally sensitive and accept-
able community- based educational interventions was 
necessary for the reduction of stroke burden291.
Expert- consensus practice guidelines
High- quality, pragmatic guidelines for the manage-
ment of stroke risk factors and treatment of stroke in 
LMICs, including Africa, are lacking. The implemen-
tation of contextually appropriate, evidence- based, 
expert- recommended stroke prevention guidelines is 
particularly important in LMICs. A systematic review of 
22 published stroke prevention guidelines found 8 from 
LMICs (36%) and 14 from high- income countries (64%) 
but only 1 from Africa (South Africa)296. LMIC- issued 
guidelines were less likely to provide clear recommen-
dations (62% versus 100%; P = 0.03), utilize high- quality 
systematic reviews (21% versus 79%; P = 0.006), engage 
in good dissemination avenues (12% versus 71%; 
P = 0.02) or invite input from an external reviewer (12% 
versus 57%; P = 0.07)296. Thus, the quality and quantity 
of expert consensus stroke management guidelines in 
Africa clearly need to improve.
Clinical trials
Increasing numbers of stroke- related clinical trials are 
being performed in Africa295,297–301 (fig. 4). The dominant 
effect of hypertension among African survivors of stroke 
means that evidence- based interventions to control this 
risk factor are an important area of research. The first ran-
domized controlled trials of hypertension control among 
survivors of stroke in Africa involved multi- modal inter-
ventions that aimed to address barriers to hypertension 
control at the level of the patient, provider and practice. 
For example, the Phone- based Interventions under Nurse 
Guidance after Stroke (PINGS) study in Ghana assessed 
the feasibility and preliminary efficacy of a domiciliary 
blood pressure- monitoring intervention that was mobile 
health technology- based and nurse led295,302. A cohort of 
60 recent survivors of stroke took part in the trial, which 
had a cluster randomized controlled design; 30 partic-
ipants received the intervention and 30 participants 
received usual care using a cluster randomized controlled 
trial design. The intervention lasted for 3 months and 
participants were followed- up for a further 3 months. 
The results indicated that the intervention is feasi-
ble and identified a possible efficacy signal in terms of 
blood pressure control. Specifically, an intention- to- treat 
analysis found that, at month 3, 67% of participants in 
the intervention group had systolic blood pressure of 
<140 mmHg compared with just 47% of participants in 
the control group (P = 0.12). At month 9, 73% of par-
ticipants in the intervention group had systolic blood 
pressure of <140 mmHg compared with 43% of the par-
ticipants in the control group (P = 0.035). Furthermore, 
medication possession ratio scores (measure of medica-
tion adherence) at month 3 and month 9 were higher in 
the intervention group than in the control group.
The Tailored Hospital- based Risk reduction to 
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Fig. 4 | Studies on stroke in Africa. Here, we summarize the published literature on stroke in Africa, from 1999 to November 
2020, and including 107 case reports or series, 29 epidemiological studies, 562 clinical studies, 5 clinical trials, 4 international 
studies, 30 genetic studies, 21 preclinical studies, 136 reviews, 52 letters or editorials, 6 clinical guidelines and 4 quality 
improvement- related publications. aIncludes community- based prevalence and incidence studies on stroke in Africa. bIncludes 
hospital- based studies, whether of observational or interventional, retrospective or prospective, longitudinal or case–control 
designs. cRefers to studies that report the testing of a drug, procedure or other medical treatment in animals, where the disease 
of interest in the study was a stroke. dIncludes narrative reviews, scoping reviews, systematic reviews and meta- analyses.
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in Nigeria was much larger than the PINGS study and 
randomized 400 survivors of stroke to two treatment 
groups. One group received usual care and the other 
received a bundled intervention that included patient 
report cards, phone text messaging, an educational 
video and co- ordination of post- hospitalization care303. 
After 12 months of administration, systolic blood pres-
sure in the group of participants receiving the THRIVES 
was not significantly lower than in the group of partic-
ipants receiving usual care. However, in a sub- group 
of participants with uncontrolled blood pressure, both 
usual care and the THRIVES intervention were associ-
ated with a reduction in blood pressure, in both arms, 
compared with the pre- treatment baseline294. An ongoing 
secondary prevention trial — the Stroke Minimization 
through Additive Anti- atherosclerotic Agents in Routine 
Treatment (SMAART) trial — is a phase II, open- label, 
evaluator- blinded trial involving 120 participants from 
Ghana who have recently survived a stroke. Participants 
were randomly allocated in a 1:1 ratio to either receive 
the intervention or usual care. Participants in the inter-
vention arm receive a polypill (Polycap DS, Cadila 
Pharmaceuticals) that contains 100 mg aspirin, 50 mg 
atenolol, 5 mg ramipril, 12.5 mg thiazide and 20 mg sim-
vastatin per capsule and taken as two capsules once daily. 
Participants in the usual care group will receive separate, 
individual secondary preventive medications prescribed 
at the physician’s discretion. Both groups will be followed 
for 12 months to assess changes in carotid intima media 
thickness regression300,301 and results are expected in late 
2021. PINGS-2 is a randomized controlled trial of a the-
oretical model- based, mobile health technology- centred, 
nurse- led, multi- level integrated approach to improve 
longer- term blood pressure control. The trial includes 
500 patients who have recently had a stroke recruited 
from 10 hospitals in Ghana and is currently ongoing304.
Evidence for an association between prevalence 
of tobacco smoking and prevalence and incidence of 
stroke in Africa is lacking. However, overall epidemi-
ological trends of cardiovascular disease can be used as 
a proxy for the burden of stroke. For example, in South 
Africa, despite the use of tobacco taxation measures to 
discourage smoking, cardiovascular disease is still one 
of the highest sources of non- communicable disease 
burden. Although selected countries in Africa are using 
such fiscal measures to reduce tobacco use, large- scale 
multi- pronged efforts that include behavioural inter-
ventions to reduce the burden of tobacco smoking are 
lacking. The reality in Africa is that there are well- known 
inequalities and inefficiencies, both among and within 
countries, that make it difficult to follow through on the 
WHO’s framework for tobacco control305.
Biobanking and precision stroke medicine
The stroke research landscape in Africa has wit-
nessed progress and diversification in the past decade. 
The increasing burden and poor outcomes of stroke 
on the African continent require an aggressive research 
agenda to identify, characterize and confront risk fac-
tors and to implement evidence- based strategies. Indeed, 
basic, clinical, translational and health systems research 
are required to reduce the burden of stroke. In particular, 
precision medicine- focused trans- omics stroke research 
approaches are gaining increasing attention while 
not abandoning the traditional public health- driven 
approaches25,306,307.
The past decade heralded an explosion of genomic 
research and biobanking in Africa, largely driven by 
Epidemiological surveillance
• Burden (incidence, prevalence, 
mortality and DALYs)
• Trends
• Causes and risk factors 
(genomic, transcriptomic and 
environmental)
Aim: to provide evidence for 
planning and designing 
interventions





Aim: to reduce incidence and 
prevalence
Acute care
• Early and accurate diagnosis 
and presentation 




Aim: to reduce mortality
Rehabilitation
Aim: to reduce DALYs and 





Fig. 5 | The stroke quadrangle. The four pillars of the stroke quadrangle are surveillance, 
prevention, acute care and rehabilitation. Together, these pillars can lead to the reduction 
of stroke incidence, prevalence, disability and mortality. DALYs, disability- adjusted  
life years.




Surveillance Valid, reliable data on stroke 
incidence, prevalence, 
mortality and disability in 
Africa are extremely limited; no 
surveillance system is in place 
to track trends in the burden of 
stroke at continental, regional 
and country levels
Establish stroke surveillance 
systems to measure and monitor 
the burden of stroke
Prevention No robust systems for detection 
and control of major stroke risk 
factors such as hypertension, 
diabetes mellitus and 
dyslipidaemia; high rates (93%) 
of uncontrolled hypertension
Increase awareness, screening 
and control of hypertension, 
dyslipidaemia, diabetes mellitus 
and other major stroke risk 
factors at the primary health- care 
level in synergy with programmes 
for NCDs; implement 
sensitization programme to 
involve the entire population 
across the lifespan
Acute care Scarcity of high- quality 
hyperacute and acute care 
services; very low rates of 
thrombolysis and thrombectomy; 
few multidisciplinary stroke units
Synergistic action by all 
stakeholders, including 
pharmaceutical companies 
and stroke experts, to improve 
the availability of services and 
increase the number of stroke 
units
Rehabilitation Few multidisciplinary stroke 
rehabilitation centres
Increase the number of 
centres and settings that offer 
multidisciplinary care; promote 
recovery and re- integration
NCDs, non- communicable diseases.
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funds provided by the Wellcome Trust and the NIH. The 
NIH- funded SIREN study is exploring the genetic archi-
tecture of stroke among Indigenous Africans. More than 
4,000 case–control pairs have already been recruited to 
the study and several publications on stroke phenom-
ics and preliminary candidate gene analyses have been 
generated. The SIREN study has also undertaken the 
first- ever GWAS to unravel the genetic architecture 
of stroke in Indigenous Africans and the results are 
eagerly awaited. Stroke neurobanking resources con-
sisting of blood fractions, extracted DNA, neuroimages 
and databases of clinical information are also being 
built in Africa and could facilitate data science- driven 
trans- omics research (including epigenomics, tran-
scriptomics, proteomics and metabolomics) as well as 
the development of precision medicine products such 
as Afrocentric risk calculators, polygenic risk scores, 
biomarkers and drug targets23–25,227,307,308. The SIREN 
neurobiobank comprises a group of constantly moni-
tored ultra- low- temperature (–86 °C) freezers located 
in Ibadan, Nigeria, constantly powered –20 °C chest 
freezers located in Ibadan and other recruitment sites, 
barcode scanners and printers, a laboratory information 
management system, a secure multi- terabyte server, 
user- friendly software for archiving neuroimages, and 
solar- powered inverter systems to provide uninter-
rupted electric power back- up272,309. The neurobiobank 
contains >3,800 brain images and 160,000 blood sam-
ples including serum, plasma, red cell concentrates and 
extracted DNA. The ethical, legal and societal implica-
tions of stroke neurobiobanking and genomics in the 
complex African sociocultural landscape are also being 
explored310.
Future directions
Stroke care in Africa faces numerous challenges related 
to epidemiological surveillance, health promotion 
and disease prevention, acute care and rehabilitation: 
the four domains of the stroke quadrangle311 (fig. 5). 
However, various pragmatic solutions to these chal-
lenges exist (Table 6). First, epidemiological surveillance 
can be improved by the establishment of a framework 
for regular monitoring and evaluation of stroke (includ-
ing burden and risk factors) and health services at the 
national level. This framework could involve a combi-
nation of community- based surveys and surveillance 
systems. Second, the implementation of integrated 
population- wide and individual prevention strategies 
could reduce exposure to and improve control of modi-
fiable risk factors. Third, the effective planning of acute 
stroke care services, including workforce training and 
capacity- building, can improve acute stroke care. Last, 
the promotion of access to interdisciplinary care, includ-
ing task sharing approaches, can improve post- stroke 
rehabilitation services. To coordinate these activities, 
the newly launched African Stroke Control Observatory 
Risk reduction Ecosystem (A- SCORE), which will be a 
major part of the global SCORE (G- SCORE) under the 
auspices of the WSO–WHO–Lancet Neurology Com-
mission on Stroke, should be enhanced253. A-SCORE 
involves policy- makers, patients, payers, providers, 
the populace and implementation partners. Through 
surveillance and research, stroke in Africa will become 
quantifiable and understandable; through prevention, 
stroke will become avoidable; through provision of 
acute care, stroke will become treatable; and through 
rehabilitation, stroke will be surmountable.
Novel stroke leadership initiatives are springing up 
in Africa and hold great promise for tackling the grow-
ing burden of stroke on the continent. For example, 
the African Stroke Organization is a new pan- African, 
multidisciplinary coalition of stroke professionals, 
stroke support organizations and national stroke soci-
eties with the vision “to reduce the burden of stroke 
in Africa”312 (fig. 6). The organization aims to achieve 
this vision through multidisciplinary research and 
capacity- building, promoting the development of effec-
tive stroke prevention and intervention services, enhanc-
ing stroke awareness, advocating for survivors of stroke, 
their families and caregivers, and driving the formulation 
of stroke- friendly policies312. Multiple non- governmental 
initiatives working as stroke support organizations are 
springing up across the continent. These organizations 
are working with survivors of stroke and their care-
givers to enhance rehabilitation and life after stroke as 
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Fig. 6 | Conceptual framework of the African Stroke Organization. The aim of the 
African Stroke Organization (ASO) is to reduce the burden of stroke in Africa. This figure 
illustrates the framework through which the ASO plans to meet this goal. The colourful 
network represents the rich genetic, cultural and geographical diversity in Africa, and 
the neuronal network of the brain. The interconnected individuals represent the African 
Ubuntu Philosophy of inclusiveness, cooperation and collaboration. The pale green layer 
depicts the four core pillars of ASO activities: research; capacity- building programmes; 
development of stroke services; promotion of stroke awareness, and advocacy and 
empowerment of survivors of stroke, their families and their caregivers. The dark green layer 
represents the broader core values of the ASO: working with partners to involve people and 
positively influence practice and policy. Adapted with permission from ref.312, SAGE.
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extant stroke prevention initiatives313. Furthermore, 
the African Stroke Organization is launching an annual 
pan- African scientific conference on stroke to regularly 
examine gaps in evidence and practice, accelerate trans-
lational research, guide priorities for stroke care practice 
and policy, build future stroke leaders, and strengthen 
regional collaboration and research output. The first 
African Stroke Organization Conference is expected to 
be held in autumn 2021 (refs314,315).
Implementation science is a distinct research pri-
ority for stroke in Africa312. Existing evidence for the 
primordial, primary and secondary prevention of stroke 
needs to be contextualized to target Africa. Barriers to 
and facilitators of vascular risk factor control, both tra-
ditional and novel, need to be unmasked. Accurate, rig-
orous and detailed epidemiological studies to track the 
trends of incidence, prevalence, case fatality and mortal-
ity, and DALYs will be required to inform detailed and 
pragmatic planning of population- based strategies to 
control the escalating stroke burden in Africa. The ongo-
ing African Rigorous Innovative Stroke Epidemiological 
Surveillance (ARISES) study was designed to address the 
methodological limitations of previous epidemiological 
studies26. This new study is also using technological 
innovations, including geographical information systems 
and mobile health- driven stroke information systems, to 
gather accurate data on incident strokes in the demo-
graphic sites where the study is being conducted. The 
mobile health- driven stroke information system will be 
deployed to improve local stroke literacy and enhance 
near- total case detection. Results are expected in 2025.
Translational interdisciplinary science, including 
trans- omics technology and data science, will be needed 
to gain deeper insight into novel stroke- associated 
genetic loci and pathophysiological pathways. These 
approaches will also enable the discovery of new, 
population- specific risk calculators, biomarkers and 
drug targets with the aim of achieving personalized, 
or precision, stroke treatment24,227. New treatments 
and novel preventive approaches are needed to inform 
clinical trials and the development of multicentre 
and multinational networks to tackle the increasing 
stroke burden.
The WSO–WHO–Lancet Neurology Commission 
on Stroke253 conducted a survey of stroke services in 
five African nations to assess needs and offer pragmatic 
solutions; however, this effort needs to be scaled up 
to cover other African countries316. Public education 
is needed to fill the unique gaps in stroke knowledge 
present in different African populations and to address 
the influence of cultural and religious beliefs and prac-
tices relating to stroke289,291. To fill the critical gaps in the 
availability of stroke professionals in Africa, focused 
training in stroke medicine needs to be incorporated 
into the curricula of postgraduate medical, nursing and 
allied professional education. Short courses and confer-
ence teachings should also be provided. Online resources 
that are sensitive to the unique epidemiological, cultural 
and socioeconomic environment in the continent will 
be very useful for filling knowledge gaps. Large multi-
national initiatives, such as the Angels Initiative and 
SITS Registry, have scaled up acute stroke services in 
Europe, the Middle East and North Africa269. We suggest 
that organizations within Africa develop partnerships 
with such initiatives to improve stroke services in Africa. 
African governments and regional organizations need to 
formulate policies that advance stroke science and care 
in Africa in tandem with their expressed commitments 
to actualize Sustainable Development Goal 3.4, which 
aims to ensure healthy lives and promote well- being 
and reduce premature death from non- communicable 
diseases, including stroke, by one- third by the year 2030.
Conclusions
Alarmingly, as the current epidemiological evidence 
shows, the scourge of stroke is on the increase in Africa. 
Modifiable risk factors such as hypertension are clearly 
key primary targets for treatment and prevention. As is 
evident from the experience of higher- income countries, 
reducing the burden of stroke incidence in Africa will 
undoubtedly reduce mortality, morbidity, disability and 
the neurological as well as cognitive sequelae associated 
with stroke. Fortunately, welcome progress has been 
made in stroke medicine, awareness, prioritization, 
care, education, research and policy- making. If such 
progress continues, the anticipated future toll of stroke 
on the continent and its over 1 billion people could be 
substantially mitigated. However, successfully building 
on current efforts is by no means guaranteed. Patients, 
providers, payers, policy- makers and the public, in con-
cert with scientists and funders, will need to maintain 
prospective vigilance of the continental stroke burden, 
apply vigour to unravelling the unique determinants 
of stroke in the region, and prioritize the development of 
contextual preventive and therapeutic solutions to avert 
and minimize the burden of stroke316.
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